Hua Medicine Announces 2020 Interim Results
New Drug Application for a potential First in Class GKA dorzagliatin accepted by NMPAExpansion of indications for dorzagliatin strengthened R&D pipelineSHANGHAI, CHINA, Aug 19, 2021 - (ACN Newswire) - Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the "Reporting Period"). During the Reporting Period, the New Drug Application (NDA) of the first glucokinase activator (GKA) dorzagliatin, has been accepted by The Center for Drug Evaluation (CDE) of the China National Medical Pro...